Navigation Links
Actinium Pharmaceuticals, Inc. Receives Notice of Patent Allowance for a Key Application
Date:5/13/2013

NEW YORK, May 13, 2013 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (OTCBB: ATNM), a biopharmaceutical company that develops innovative targeted payload immunotherapeutics for treatment of advanced cancers, announced that the U.S. Patent and Trademark Office (USPTO) has allowed a key patent application in the Company's portfolio.  The patent application "Alpha Emitting Constructs and Uses Thereof" is licensed by Actinium Pharmaceuticals from Memorial Sloan Kettering Cancer Center (MSKCC). 

The application covers treatment of metastatic solid cancers by targeting either cancer cells directly or blood vessels that provide for their growth with appropriate carriers of alpha emitting isotopes actinium 225 and bismuth 213.  This technology allows Actinium Pharmaceuticals to expand use of its platform beyond blood borne and bone marrow located cancers, thus potentially offering broad categories of severely ill patients an efficacious therapy with a safety profile that could allow treatment of such patients.  The patent is expected to issue in the next few months. Actinium Pharmaceuticals retains an exclusive license to use, develop, and commercialize this patent.

Dragan Cicic , MD, CMO of Actinium Pharmaceuticals, said: "This decision is an important step towards our goal of expanding the use of our technology to address the vast unmet medical need area of metastatic cancers in older patients.  We have the potential to not only improve efficacy of cancer treatment but also enable it in many patients too sick to withstand the rigors of currently available therapies."

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc.  is a New York, NY based biopharmaceutical company that develops innovative alpha particle immunotherapeutics based on its proprietary platform for the therapeutic utilization of alpha particle emitting actinium-225 and bismuth-213 radiopharmaceuticals in association with monoclonal antibodies.

For more information:

Visit our web site www.actiniumpharmaceuticals.com or Contact:

Segio Traversa , CEO
Actinium Pharmaceuticals Inc.
E-mail: straversa@actiniumpharmaceuticals.com

Media:
Dennis S. Dobson Jr. , 203-258-0159
Email: dsdobson@optonline.com 
www.dobsonmediagroup.com

Forward-Looking Statement for Actinium Pharmaceuticals, Inc.

This news release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance.  No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.


'/>"/>
SOURCE Actinium Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Cactus Ventures, Inc. Changes Name to Actinium Pharmaceuticals, Inc.
2. Actinium Pharmaceuticals, Inc. To Present at the 15th Annual BIO CEO Investor Conference
3. Actinium Pharmaceuticals to Present at EMIT Targeted Radiotherapy Conference
4. University of Pennsylvania joins Actinium Pharmaceuticals Multicenter Actimab-A Trial
5. Additional Clinical Data from Two Trials on Actinium Pharmaceuticals Iomab-B to be Presented at American Society of Hematology (ASH) Annual Meeting
6. Actinium Pharmaceuticals Sponsors Webinar on Clinical Use of Alpha Immunotherapy
7. Actinium Pharmaceuticals Announces New Round of Financing
8. Gerri Henwood Joins Actinium Pharmaceuticals as Chief Development Officer
9. Actinium Pharmaceuticals Commences Screening for the Second Cohort of Patients in the Companys Ongoing Phase I/II Trial in Acute Myeloid Leukemia
10. Actinium Pharmaceuticals Stockholders Vote to Approve Fundraising and Public Listing
11. Actinium Pharmaceuticals Strengthens Management Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... BOSTON , April 20, 2017   ZappRx, Inc ... the specialty drug prescribing process, today announced it closed $25 ... Fund, a venture capital firm based in Seattle ... Qiming Venture Partners . The Series B round included ... A round in 2014, and GV (formerly Google ...
(Date:4/20/2017)... Research and Markets has announced the addition of the ... Service (Manufacturing, Research), By Country, (Brazil, Mexico, Colombia, Argentina, Chile, ... their offering. ... Latin American pharmaceutical contract manufacturing services market is anticipated to ... registration cost in Latin American countries and continuous economic growth ...
(Date:4/19/2017)... NEW YORK , April 19, 2017 ... Surgical drainage devices are tubes used to remove excess ... include, blood, serum, pus, urine, bile or lymph. Surgical ... types of surgery such as orthopedics surgery, cardiovascular surgery, ... device is prophylactic post-surgery to prevent accumulation of fluid ...
Breaking Medicine Technology:
(Date:4/24/2017)... ... April 24, 2017 , ... As part of the nationwide ... honor the victims of the Holocaust and Nazi persecution, Center for Medicine after ... Auschwitz on its CMATH Champions trip to Germany and Poland next week. , The ...
(Date:4/24/2017)... TX (PRWEB) , ... April 24, 2017 , ... The ... the glitterati, those unreal icons inhabiting the rarified air of pop and film stardom.(1) ... paparazzi and anyone snapping pictures: the smile. Grins now run the gamut from being ...
(Date:4/24/2017)... Calif. (PRWEB) , ... April 24, 2017 , ... The ... $1.6 million in charitable dental services to 1,961 people during the April 22-23 event ... at no charge to Californians who experience barriers to care, CDA Cares educates the ...
(Date:4/24/2017)... ... 24, 2017 , ... Veteran Theresa James awoke to the sound of her ... In “Healing Tears,” James depicts every parent’s worst nightmare, when her three children were ... conversations and situations throughout my divorce,” James said. “After the death of my children, ...
(Date:4/24/2017)... Boca Raton, Florida (PRWEB) , ... April 24, ... ... that develops a variety of unique liquid food supplements, announced its popular products ... of nutritional products. , ALP Nutrition® prioritizes the use of premium natural ...
Breaking Medicine News(10 mins):